Anthony L Boral

Title: The Innovations of Anthony L. Boral

Introduction

Anthony L. Boral is an accomplished inventor based in Cambridge, MA. He is known for his significant contributions to the field of pharmaceuticals, particularly in the treatment of indolent systemic mastocytosis. His work has led to the development of innovative dosing regimens that have the potential to improve patient outcomes.

Latest Patents

Anthony L. Boral holds a patent for "Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis." This patent includes crystalline forms of the compound, pharmaceutically acceptable salts, and solvates. It also discloses pharmaceutical compositions, methods for treating disorders associated with oncogenic KIT and PDGFRA alterations, and methods for making the compound and its crystalline forms.

Career Highlights

Anthony L. Boral is currently associated with Blueprint Medicines Corporation, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing treatments that target specific genetic alterations in cancer.

Collaborations

Anthony has collaborated with notable colleagues such as Brenton Mar and Hui-Min Lin, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Anthony L. Boral's contributions to pharmaceutical innovations exemplify the impact of dedicated inventors in the medical field. His patent work and collaborations highlight the importance of research in developing effective treatments for complex diseases.